GlaxoSmithKline backs a preclinical acne treatment from Eligo Bioscience that uses CRISPR to kill bacteria
Roughly three and a half years since bagging a $20 million financing round to develop its CRISPR-based microbiome modulation platform, Eligo Bioscience has made its first deal with a major pharma player. And it’s one who’s typically on the lookout for new precision medicines.
The French biotech locked down a partnership with GlaxoSmithKline for up to $224 million, the companies announced Monday, aiming to adapt Eligo’s technology into a treatment for the bacteria that causes acne. Under the agreement, Eligo will receive an upfront payment and R&D funding to take the program through the proof of concept phase, after which GSK can exercise an option to license the candidate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.